Grifols to Evaluate New Immunoglobulin Therapy Against COVID-19 in Spain
Clinical Trials
Sarepta Reports Mixed Results of SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) in Part 1
Shots: The Study 102 involves assessing of SRP-9001 vs PBO in 41 patients in a ratio (1:1) with DMD aged 4-7yrs. Results: @12wks. post treatment, the study met its 1EPs of micro-dystrophin protein expression, as measured by western blot. @48wks. increase in NSAA total score, however, the study did not achieve significance on the primary […]Read More
